VOchsner Health

Single-Patient Nurse Mixing Instruction Sheet

Non-24/7 Pharmacies and Free-Standing Emergency Department

alteplase (ACtivase) 100 mg injection SUPPLIES include quantity and medication name, strength/concentration, volume, diluent, diluent volume, and quantity and name of each supply needed ***NS flush syringes are never to be used for reconstitution/diluent for medication.*** One (1) alteplase kit, which contains one (1) 100 mg alteplase powder vial packaged with one (1) diluent for reconstitution 100 mL sterile water for injection (SWFI) vial and one (1) transfer device Alcohol swabs Two-three (2-3) 18 gauge needles preferred (20-23 gauge needles acceptable) • One (1) 50 mL sterile syringe • One (1) appropriate syringe size for patient specific dose • Nursing IV admixture label(s) – Lawson # 626 • STEPS explicitly state each step in chronological order, including hand washing, gown/garb, alcohol swab, etc.) NOTE: instructions below and picture diagrams are available in the package insert located in the kit carton. 1. Wash hands. Prepare/clean the designated mixing area. 2. Flip the cap off of the 100 mg alteplase vial and 100 mL SWFI vial and wipe the rubber stoppers with alcohol swabs. 3. Remove cover from one end of transfer device. Do not wipe transfer device spikes with alcohol. (Note: Either side of transfer device can be used). Insert spike straight through center of SWFI vial stopper. Remove cover from other end of transfer device. 5. Hold the alteplase vial upside down over spike. Press alteplase vial down to insert spike straight through center of Activase vial stopper. 6. Invert the two vials so that the SWFI vial is on top. Allow all SWFI to transfer into alteplase vial. If the flow does not start immediately or pauses, initiate the flow by flipping and re-inverting the vials. 7. Swirl gently and/or invert slowly to dissolve alteplase powder. Do not shake. 8. Remove the transfer device and the empty SWFI vial from the Activase vial and discard. 9. Visually inspect solution (e.g. free of inappropriate visible particulates or other foreign matter, discoloration, and defect), and the container integrity is intact. Discard if any defects. 10. Label the vial containing reconstituted solution with: a. Drug name, strength, and dose (if not apparent by the container) b. Diluent and volume (if not apparent by the container) c. Hang-by date and time (administration must begin within 1 hour from the time of compounding) d. Initials of person compounding 11. If syringe for IV push is needed: a. Attach 18 gauge needle to appropriate size syringe and withdraw patient-specific dose per order from the reconstituted alteplase vial. b. Visually inspect the final syringe for particulate matter/defects. Discard if any defects. Discard the alteplase vial once dose is withdrawn. c. Label the final syringe with the following information: i. Patient name and location ii. Drug name, strength, and dose (if not apparent by the container) iii. Diluent and volume (if not apparent by the container) iv. Hang-by date and time (administration must begin within 1 hour from the time of compounding) v. Initials of person compounding References alteplase (Activase) for injection [prescribing information]. South San Francisco, CA: Genentech, Inc. Revised 9/2022. https://dailymed.nlm.nih.gov/dailymed/fda/fda/rugXsl.cfm?setid=c669f77c-fa48-478b-a14b-80b20a0139c2&type=display. United States Pharmacopeia (USP). General Chapter, <797> Pharmaceutical Compounding—Sterile Preparations. (2023) USP-NF. Rockville, MD: United States Pharmacopeia.

https://ochsnerhealth.sharepoint.com/sites/ClinicalResources/SiteAssets/Forms/AllItems.aspx?id=%2Fsites%2FClinicalResources%2FSiteAssets%2FSitePages%2FRegulatory%2DReadiness%2FUSP%2D797%2DOfficial%2D11%2E1%2E23%2Epdf&parent=%2Fsites%2FClinicalResources%2FSiteAssets%2FSitePages%2FRegulatory%2DReadiness